1. Home
  2. ENSG vs NUVL Comparison

ENSG vs NUVL Comparison

Compare ENSG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Ensign Group Inc.

ENSG

The Ensign Group Inc.

HOLD

Current Price

$147.23

Market Cap

10.0B

Sector

Health Care

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.45

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENSG
NUVL
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0B
9.8B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
ENSG
NUVL
Price
$147.23
$123.45
Analyst Decision
Buy
Strong Buy
Analyst Count
5
16
Target Price
$202.60
$134.75
AVG Volume (30 Days)
640.3K
2.7M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
0.14%
N/A
EPS Growth
14.06
N/A
EPS
1.67
N/A
Revenue
$5,057,841,000.00
N/A
Revenue This Year
$17.07
N/A
Revenue Next Year
$9.49
$1,239.49
P/E Ratio
$90.81
N/A
Revenue Growth
18.72
N/A
52 Week Low
$134.80
$71.14
52 Week High
$218.00
$123.62

Technical Indicators

Market Signals
Indicator
ENSG
NUVL
Relative Strength Index (RSI) 23.21 66.62
Support Level N/A $97.71
Resistance Level $181.79 N/A
Average True Range (ATR) 5.97 4.24
MACD -1.48 2.74
Stochastic Oscillator 20.30 99.49

Price Performance

Historical Comparison
ENSG
NUVL

About ENSG The Ensign Group Inc.

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: